Expression of a specific extracellular matrix signature is a favourable prognostic factor in acute myeloid leukemia

Publication date: Available online 13 December 2017 Source:Leukemia Research Reports Author(s): Valerio Izzi, Juho Lakkala, Raman Devarajan, Eeva-Riitta Savolainen, Pirjo Koistinen, Ritva Heljasvaara, Taina Pihlajaniemi Relapse of acute myeloid leukemia (AML) are still dramatically frequent, imposing the need for early markers to quantify such risk. Recent evidence point to a prominent role for extracellular matrix (ECM) in AML, but its prognostic value has not yet been investigated. Here we have investigated whether the expression of a 15-ECM gene signature could be applied to clinical AML research evaluating a retrospective cohort of 61 AML patients and 12 healthy donors. Results show that patients whose ECM signature expression is at least twice as that of healthy donors have considerably longer relapse-free survival, with further stage-specific therapy outcomes.
Source: Leukemia Research Reports - Category: Hematology Source Type: research